Company: BIVIW
Filing Date: 2025-05-15
Form Type: DRS
Source: 0001520138-25-000149
Chunk: 49

Company: BIOVIE INC.
Filing Date: 2025-05-15
Form: DRS
Chunk 49
---
 case within the meaning
of Section 16 of the Exchange Act with respect to any Relevant Security or otherwise enter into any swap, derivative or other transaction
or arrangement that transfers to another, in whole or in part, any economic consequence of ownership of a Relevant Security, whether or
not such transaction is to be settled by the delivery of Relevant Securities, other securities, cash or other consideration, or otherwise
publicly disclose the intention to do so.

Right of First Refusal

We have granted the Representative an irrevocable
right of first refusal (the “Right of First Refusal”), for a period of 12 months after the date of the underwriting agreement,
provided that the Securities are sold in this offering for aggregate net proceeds of not less than $5 million, to act, except as set forth
below, as sole financial advisor, sole investment banker, sole book-runner and/or sole placement agent, at the Representative’s
sole discretion, for each and every (i) any disposition or acquisition of business units or acquisition of any outstanding securities
or any exchange or tender offer or merger, consolidation or other business combination or any recapitalization, reorganization, restructuring
or other similar transaction; (ii) any financing or refinancing of any indebtedness; or (iii) future public and private equity offering
that is not an “at-the-market” offering (an “ATM”) (an ATM executed through a broker dealer as sales agent), and
sole investment banker, sole book-runner and/or sole placement agent, at the Representative’s sole discretion, for each and every
future debt offering (items (i), (ii) and (iii), a “Future Transaction”), including all equity linked financings, during such
twelve (12) month period for the Company, or any successor to or any subsidiary of the Company, on reasonable and customary terms, provided
a Future Transaction shall not be deemed to include, and no Right of First Refusal is granted to the Representative in connection with,
any of the following: (a) any equity securities directly issued by the Company pursuant to acquisitions or strategic transactions, including
as part of any grant funding from a third party, or (b) any offer or sale of equity securities by the Company directly to non-U.S. persons
domiciled in the following jurisdictions: China, Korea, Latin America (e.g. the Caribbean and/or the Cayman Islands) and Middle East,
in each case, in a private placement not otherwise involving a public